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ABSTRACT 
Purpose. Artificial tears are widely used in the treatment of dry eye disease, although current 
formulations do not closely resemble natural tears. The purpose of this study was the design 
and characterization of a novel in situ gelling artificial tear formulation, containing both lipid 
and aqueous components, in order to resemble natural tears and replenish the tear film.  
Methods. Liposomes, containing phosphatidylcholine, cholesterol, vitamins A and E, were 
prepared by the thin-film hydration method. The aqueous phase of the formulation was 
comprised of gellan gum, hydroxypropyl methylcellulose, levocarnitine, electrolytes (sodium 
chloride and potassium chloride), trehalose, and borates. The artificial tear was characterized 
in terms of liposome size, pH, surface tension, and viscosity. In vitro tolerance studies were 
performed in a human epithelial carcinoma cell line (HeLa) and a murine macrophage cell 
line (J774). In vivo tolerance was assessed in rabbits. 
Results. Liposomes presented a unimodal distribution with a mean size of 200.1 ± 4.4 nm. 
The resulting surface tension was 53.4 ± 1.1 mN/m (at 33°C) and the pH was 7.6 ± 0.1. The 
viscosity of the formulation presented a mean value of 4.0 ± 0.1 mPa.s within the shear rate 
interval of 200-1000 s-1 at 33°C. Cell viability remained higher than 90% in both cell lines. 
No discomfort or clinical signs were observed in rabbits. 
Conclusions. The liposome-based and in situ gelling artificial tear formulation presented 
good tolerance and suitable properties for topical ophthalmic administration. It may be 
beneficial in the treatment of dry eye disease.  
Keywords: dry eye, artificial tear, liposome, in situ gel, nanotechnology 
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HIGHLIGHTS 
▪ A novel liposome-based, in situ gelling artificial tear formulation was developed. 
▪ Physicochemical properties, in vitro and in vivo tolerance were evaluated. 
▪ The formulation showed suitable properties for topical ophthalmic administration. 
▪ Good in vitro and in vivo tolerance was observed.  
▪ The novel artificial tear may be beneficial in the treatment of dry eye disease. 
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INTRODUCTION 
Dry eye disease (DED) is a highly prevalent health problem affecting approximately 5-35% 
of the world’s population [1]. It is defined as a multifactorial disease of the tears and ocular 
surface that results in symptoms of discomfort, visual disturbance and tear film instability [2]. 
DED is associated with a significant adverse impact on vision-related quality of life, causing 
difficulties in daily activities [3,4]. It can be caused by various factors such as meibomian 
gland dysfunction, low blink rate, ocular surface disorders and contact lens wear, among 
others, resulting in the alteration of the tear film [2]. 
Artificial tears are widely used for mild to moderate dry eye, and can be prescribed in 
combination with other therapies for moderate to severe dry eye. Numerous artificial tear 
formulations with a diverse range of components are currently available in the market; 
however, most of these formulations do not quite resemble the composition of natural tears 
[5]. Furthermore, they have a short ocular residence time and require repeated daily 
administration.   
An ideal artificial tear formulation should contain both aqueous and lipid components to 
mimic natural tears, and have certain physicochemical properties such as hypotonicity or 
isotonicity, neutral to slightly alkaline pH, suitable surface tension and viscosity [6]. A 
surface tension near the physiological range of natural tears, that is reported to be 40-46 
mN/m [7,8], provides a good spreading of the formulation over the ocular surface. For 
artificial tears that follow Newtonian behavior, the desirable viscosity would be in the 
physiological range of 1.0-8.3 mPa.s [9,10]; whereas for those that follow non-Newtonian 
behavior, a dynamic viscosity in the same range would be suitable. Additionally, an ideal 
artificial tear formulation should be well tolerated on the ocular surface, provide extended 
ocular residence time, and be preservative-free. This study aimed at designing a novel 
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liposome-based and in situ gelling artificial tear formulation having such properties to 
replenish the tear film, with potential beneficial effects for the treatment of DED. 
 
MATERIALS AND METHODS 
Materials 
Phosphatidylcholine obtained from soy lecithin (Phospholipon® 90 G) was purchased from 
Lipoid GmbH (Ludwigshafen, Germany). Cholesterol, retinyl acetate (vitamin A), DL-α-
tocopherol acetate (vitamin E), gellan gum (Gelzan™ CM, Gelrite®), boric acid, sodium 
tetraborate anhydrous, and benzalkonium chloride were supplied by Sigma-Aldrich Co. (St. 
Louis, MO, USA). Hydroxypropyl methylcellulose was purchased from Abarán Materias 
Primas S.L. (Madrid, Spain), levocarnitine from Fagron Ibérica SAU (Barcelona, Spain), and 
D-(+)-trehalose dihydrate from ThermoFisher (Kandel) GmbH (Karlsruhe, Germany). 
Sodium chloride and potassium chloride were supplied by Merck KGaA (Darmstadt, 
Germany), and chloroform (stabilized with ethanol) by Panreac Química SLU (Barcelona, 
Spain).  
 
Animals 
Six male New Zealand white rabbits (purchased from San Bernardo Farm, Navarra, Spain), 
weighing between 3.0 to 3.5 kg, were used for this study. The animals were housed 
individually with free access to food and drinking water, in a room with an alternating 12-
hour light/dark cycle. The room was maintained at 22°C with 50% relative humidity. The 
animal experiments were performed in accordance with the EU Directive 2010/63/EU for 
animal experiments, U.K. Animals (Scientific Procedures) Act 1986, and ARVO Statement 
for the Use of Animals in Ophthalmic and Visual Research. The study protocol was approved 
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by the Animal Experimentation Ethics Committee of the Complutense University of Madrid 
and by the Community of Madrid (approval reference: PROEX 011/16). 
 
Preparation of the artificial tear formulation 
Liposomes were prepared by the thin-film hydration method described by Bangham et al. 
[11] and modified by Vicario-de-la-Torre et al. [12]. 400 mg of phosphatidylcholine (PC), 50 
mg of cholesterol (Chol), 4 mg of vitamin E (vit E), and 400 ng of vitamin A (vit A) were 
dissolved in 25 mL of chloroform. The solvent was evaporated in a rotary evaporator (Büchi 
Rotavapor R-205, Massó Analítica S.A., Spain). The resulting dry lipid film was hydrated 
with 10 mL of an aqueous medium composed of 1.68% trehalose, 0.84% boric acid (H3BO3), 
and 0.08% sodium tetraborate anhydrous (Na2B4O7). To obtain a homogenous population of 
lipid vesicles, the liposomal suspension was sonicated (Ultrasons-H, J.P. Selecta S.A., 
Barcelona, Spain), and extruded (Lipex® Extruder, Transferra Nanosciences Inc., Burnaby, 
BC, Canada), being forced through polycarbonate filters (Nuclepore™, Whatman 
International Ltd., Kent, UK) with a pore size of 0.2 μm. 
The liposomal suspension was diluted with solutions of gellan gum, hydroxypropyl 
methylcellulose (HPMC), levocarnitine (L-carnitine), sodium chloride (NaCl) and potassium 
chloride (KCl) to obtain the final artificial tear formulation (Table 1). The preparation was 
performed under aseptic conditions. The aqueous medium, polymer and electrolyte solutions 
underwent steam sterilization, whereas the L-carnitine solution was sterilized by filtration. 
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Table 1. Composition of the artificial tear formulation. 
Formulation 
component 
Concentration 
(% weight/volume) 
PC (liposomes)   0.5 
Gellan gum  0.25 
HPMC  0.12 
L-carnitine  0.1 
Vit E  0.005 
Vit A  0.0005 
NaCl  0.05 
KCl  0.05 
Trehalose  1.68 
H3BO3  0.84 
Na2B4O7  0.08 
 
Characterization of the artificial tear formulation 
The particle size and the size distribution profile of liposomal nanoparticles were determined 
at room temperature by dynamic light scattering (Microtrac® Zetatrac™ Particle Size & Zeta 
Potential Analyzer, Microtrac Europe GmbH, Meerbusch, Germany).  
The pH of the formulation was determined at room temperature with a calibrated pH meter 
(GLP 22, Crison Instruments S.A., Barcelona, Spain). The surface tension was measured with 
a tensiometer (Krüss K-11 Tensiometer, Krüss GmbH, Hamburg, Germany) according to the 
Wilhelmy plate method. Measurements were performed at 33°C, which corresponds to the 
temperature of the ocular surface. The viscosity of the artificial tear was determined with a 
rheometer (HAAKE RheoStress 1, ThermoFisher Scientific), using the parallel plate system 
(plate diameter 60 mm, separation 0.5 mm) at 33°C. The shear rate was increased in 20 steps 
from 0 to 1000 s-1. All measurements were performed in triplicate. 
 
In vitro tolerance studies 
The in vitro tolerance of the formulation was assessed by means of cell viability 
measurements in a human epithelial carcinoma cell line (HeLa) and a murine macrophage 
8 
 
cell line (J774). Cellular reduction of the tetrazolium salt MTT to formazan [13] was 
evaluated after cells were exposed to the formulation for 2 hours.  
 
In vivo tolerance studies 
The in vivo tolerance studies were performed in six male New Zealand white rabbits; 30 μL 
of the artificial tear was administered in the right eye of each animal every 30 minutes for 6 
hours, whereas the contralateral eye received the same volume of isotonic saline solution and 
served as control. Macroscopic evaluation of the ocular surface and the clinical signs was 
performed before the first instillation, and at 3, 6, and 24 hours after the first instillation, in 
compliance with the protocol described by Enríquez de Salamanca et al. [14]. Corneal 
opacity, conjunctival alterations, discharge, eyelid swelling, and animal discomfort as evident 
by intense blinking were examined and graded from 0 to 2. 
 
RESULTS  
Characterization of the artificial tear formulation 
The results obtained in the characterization of the physicochemical properties of the artificial 
tear are reported in Table 2. Data were expressed as mean ± standard deviation (SD).  
 
Table 2. Physicochemical properties of the artificial tear formulation. 
Property Mean ± SD 
Liposome size (nm) 200.1 ± 4.4 
pH 7.6 ± 0.1 
Surface tension (mN/m) 53.4 ± 1.1 
Viscositya (mPa.s) 4.0 ± 0.1 
aWithin the shear rate interval of 200-1000 s-1. 
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The liposomal nanoparticles of the formulation showed a unimodal size distribution (Figure 
1). The rheological properties of the artificial tear followed Newtonian behavior (Figure 2). 
 
 
Figure 1. Size distribution of the liposomal vesicles of the artificial tear formulation. The 
liposomal nanoparticles showed a unimodal size distribution, determined by dynamic light 
scattering. 
 
 
 
Figure 2. Rheogram of the artificial tear formulation. The rheological properties of the 
artificial tear followed Newtonian behavior within the shear rate interval of 200-1000 s-1. 
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In vitro tolerance studies 
Cell viability resulted in 95.0 ± 4.8% in HeLa cell line and 108.7 ± 10.4% in J774 cell line 
after exposures of 2 hours (Figure 3). 
 
 
 
 
Figure 3. Cell viability of HeLa and J774 cells after a 2-hour exposure to the artificial tear 
formulation. Untreated cells were used as negative control (100% cell viability), cells treated 
with a solution of 0.005% benzalkonium chloride (BAK) as positive control (cell death), and 
cells treated with a solution of 0.9% NaCl as reference. Cell viability was measured by MTT 
assay and resulted in higher than 90% in both cell lines. 
 
In vivo tolerance studies 
Prior to the experiment, all of the six animals had a normal ocular surface and showed no 
clinical signs or discomfort. During the experiment, the animals showed neither discomfort 
nor clinical signs (grade 0) within 24 hours after the first instillation of the artificial tear.  
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DISCUSSION 
DED is associated with alterations and instability of the tear film; therefore, restoring the tear 
film is fundamental in its management. This study aimed at developing a novel artificial tear 
formulation that resembles natural tears and replenishes the tear film. Liposomes, consisting 
of PC and Chol, were employed to replenish the lipids of the tear film. The in situ gelling 
polymer gellan gum was incorporated because of its unique gel-forming property when in 
contact with certain ions present in tears [15–18], with the aim of resisting the natural 
drainage and extending the ocular residence time of the formulation. HPMC was used to 
provide bioadhesion [19] and increase the ocular residence time. Antioxidants vit A and vit E, 
and osmoprotectants L-carnitine and trehalose were incorporated to enhance the potential 
efficacy of the artificial tear in the treatment of DED.   
When formulating an artificial tear, the key physicochemical parameters such as pH, surface 
tension, and viscosity should be taken into consideration. Human tears have a pH of 7.0-7.5 
[20,21], and a buffering capacity that prevents the ophthalmic formulations within the pH 
range of 6.6-9.0 from causing discomfort [22–24]. The surface tension of natural tears is 
reported to be 40-46 mN/m [7,8], and the viscosity 1.0-8.3 mPa.s [9,10]. The surface tension 
of an ophthalmic formulation affects its interaction with the tear film and spreading ability 
over the ocular surface [25]. The viscosity, if excessively high, can cause non-uniform 
mixing of the formulation with natural tears, blurred vision and discomfort. The 
physicochemical properties of the artificial tear developed in this study, namely the slightly 
alkaline pH (7.6), a viscosity in the physiological range of natural tears (4.0 mPa.s), and a 
surface tension close to that of natural tears (53.4 mN/m), all together suggest good spreading 
of the formulation over the ocular surface without causing tear film instability, blurred vision 
or discomfort. Furthermore, the liposomal nanoparticles of the artificial tear had a suitable 
size for a topical ophthalmic formulation. 
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The artificial tear demonstrated absence of toxicity in both HeLa and J774 cell lines. The 
formulation did not cause any discomfort or clinical signs in rabbits, indicating good in vivo 
tolerance. 
In conclusion, the results obtained in this study demonstrated that the liposome-based in situ 
gelling artificial tear formulation presents suitable properties for topical ophthalmic 
administration and is well tolerated. Due to its potential of replenishing the tear film lipids, 
restoring the tear film, and protecting the corneal epithelium, the novel artificial tear 
developed in this study may be beneficial in the treatment of DED.  
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